Recombinant SARS-CoV-2 Papain-Like Protease Protein

Catalog Number: PKSR030472



Note: Centrifuge before opening to ensure complete recovery of vial contents.

				ption		
	06		TO T	m	11	\mathbf{n}
v					ш	w

 Species
 SARS-CoV-2

 Mol_Mass
 35.8 kDa

 Accession
 QHD43415.1

Bio-activity Not validated for activity

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin $< 1.0 \text{ EU} \text{ per } \mu\text{g}$ of the protein as determined by the LAL method.

Storage Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel


packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μM filtered solution of 20mM Tris-HCl, 10 mM 2-Mercaptoethanol,

20% Glycerol, pH 7.5.

Reconstitution Not Applicable

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and delSGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.

For Research Use Only